The Company's announcement to the creditor due to
the spin off
Date of events
2022/04/11
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/04/11
2.Company name:Bora Pharmaceuticals Co., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:To integrate and specialize the Company's
CDMO and dealer business, Bora Pharmaceuticals Co., LTD.'
Board pass the resolution on 2022/04/11 to spin of the
Company's pharmaceuticals department to 100% owned subsidiary
Bora Health Inc. The preliminary reference date of the merger
is set to be 2022/05/31.
6.Countermeasures:To issue material information
7.Any other matters that need to be specified:The company shall
make an announcement to the Company's creditors in accordance
with the local regulations. When the Company's creditors have
any objection to this division, please mail or delivery the proof
of debt in person to 6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd.,
Neihu Dist., Taipei City. When no objection is expressed within
the time limit, it shall mean there is no objection.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 11 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 April 2022 16:00:31 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
